Testicular cancer and sperm DNA damage: short- and long-term effects of antineoplastic treatment by Paoli, Donatella et al.
ORIGINAL ARTICLE
Correspondence:
Loredana Gandini, Laboratory of Seminology-
Sperm Bank, Department of Experimental
Medicine, University of Rome “La Sapienza”, Viale
del Policlinico 155, 00161 Roma, Italy.
E-mail: loredana.gandini@uniroma1.it
Keywords:
chemotherapy, chromatin, DNA damage,
radiotherapy, SCSA
Received: 21-Oct-2013
Revised: 9-Jun-2014
Accepted: 20-Jun-2014
doi: 10.1111/j.2047-2927.2014.00250.x
Testicular cancer and sperm DNA
damage: short- and long-term
effects of antineoplastic treatment
1D. Paoli, 1M. Gallo, 1F. Rizzo, 2M. Spano, 2G. Leter, 1F. Lombardo,
1A. Lenzi and 1L. Gandini
1Laboratory of Seminology-Sperm Bank, Department of Experimental Medicine, University of Rome
“La Sapienza”, and 2Laboratory of Toxicology, Unit of Radiation Biology and Human Health, ENEA
Casaccia Research Centre, Rome, Italy
SUMMARY
The aim of this study was to investigate sperm DNA damage induced by chemo- and radiotherapy in patients with testicular cancer
to provide data on the extent and persistence of nuclear damage that might affect individual reproductive potential. We evaluated
pre- and post-antineoplastic treatment sperm DNA integrity, expressed as DNA Fragmentation Index (DFI), in a large caseload of
testicular cancer patients by sperm chromatin structure assay. The mean total DFI for all patients at T0 was 18.0  12.5%. Sperm
chromatin profile was markedly impaired at T3 (27.7  17.4%) and T6 (23.2  15.3%), improving considerably at T12 and T24
(14.0  8.9% and 14.4  10.3%). After chemotherapy, we found a marked increase in DFI at T3 and T6 and a significant reduction
at T12 and T24 in comparison with the baseline. In contrast, DFI increased at T3 and T6 after radiotherapy but the subsequent
reduction was far less marked, reaching baseline values at T12 and T24. Finally, post-treatment DNA damage was not age or
histotype dependent, but was more marked in the advanced stage of cancer. In this study, we showed that the chromatin profile may
be affected in the months immediately following the end of the treatment, improving after 12–24 months. Our results thus indicate
that post-treatment DNA damage is influenced both by the type and intensity of the therapy and by the pathological and clinical
stage of the disease.
INTRODUCTION
Testicular cancer is the most common cancer in men of repro-
ductive age. Although the international incidence varies consid-
erably, with large variations in different countries and among
different ethnic groups, there has been a general rise over the
last 30–40 years (Huyghe et al., 2003; Purdue et al., 2005; Chia
et al., 2010). It is particularly prevalent in European populations
and men of European ancestry (Purdue et al., 2005), with the
highest incidence in Northern Europe (8.0–9.0 per 100 000) and
lowest in Asia and Africa (<1 per 100 000) (Chia et al., 2010). As
in many other Western countries, the incidence in Italy has
risen, from a mean of 3.7 cases/year per 100 000 inhabitants in
1993–1995 to 5.2 in 2003–2005, an increase of 40.5% (Crocetti
et al., 2009). Fortunately, progress in multimodal treatments
such as chemotherapy and radiotherapy in combination with
surgery over the last 20–25 years have made testicular cancer
one of the most treatable of all cancers, especially when diag-
nosed early. For example, the estimated 5-year mortality rate is
4% in the United States (Rosen et al., 2011), whereas in Italy, it
accounted for just 0.1% of all deaths from cancer between 1998
and 2002 (AIRTUM – Associazione Italiana Registri Tumori,
www.registri-tumori.it). Today, the 5-year survival rate is above
90% (Kopp et al., 2006). Post-treatment quality of life is thus an
important aspect in the management of testicular cancer in
young men, especially with respect to fertility and the possibility
of future fatherhood.
Various studies of the effect of testicular cancer treatments on
spermatogenesis have found a post-treatment impairment of
semen parameters (Dohle, 2010; Trost & Brannigan, 2012). In
fact, while these treatments effectively kill cancer cells, they can
also affect cells with a fast replication rate, such as germ cells.
Gandini et al. (2006) showed that the most detrimental effects of
chemotherapy and radiotherapy protocols on spermatogenesis
last up to 3–6 months after treatment, with 94% of chemother-
apy patients showing good recovery after 12 months and 97%
after 24 months.
Not only semen parameters may be affected. Some studies
have also found increased sperm DNA damage and aneuploidy
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in men (Stahl et al., 2004; Tempest et al., 2008; O’Flaherty et al.,
2010) and impaired germ cell gene expression in animal models
(Delbes et al., 2009). To date, however, few studies have been
conducted on the effects on the offspring of men who have
undergone cancer treatments (Brinkworth, 2000; Stahl et al.,
2011; Signorello et al., 2012). Animal studies have shown that
chromatin damage in spermatozoa from animals exposed to
antineoplastic agents can impair the embryonic development of
offspring (Trasler et al., 1986; Bieber et al., 2006). For this rea-
son, and because of the youth of many testicular cancer patients,
there has been great concern in recent years about the effects of
antineoplastic treatment on sperm chromatin quality. Several
reports have suggested that the recovery of spermatogenesis
depends on the drugs used and on the cumulative dose given
(Dohle, 2010) and is a function of the time since the end of the
therapy (Gandini et al., 2006). However, there is still a lack of
data on chromatin and DNA damage after exposure to antineo-
plastic treatments, with the extent and duration of such damage
(and thus the time necessary for its reversal) still unknown. This
information is highly important, especially for oncologists hav-
ing to manage young patients who may still wish to father chil-
dren in the future. The aim of this study was thus to investigate
sperm DNA damage induced by antineoplastic therapies in
patients with testicular cancer to provide data on the extent and
persistence of nuclear damage that might affect individual
reproductive potential.
MATERIALS ANDMETHODS
Patients
The study was approved by our University Hospital’s
institutional review board. We studied chromatin integrity
and semen quality in 254 patients with testicular cancer who
cryobanked spermatozoa at the Seminology Laboratory-Sperm
Bank, Department of Experimental Medicine, University of
Rome “La Sapienza” after orchiectomy and before beginning
chemotherapy or radiotherapy.
This longitudinal study evaluated patients pre- and post
treatment at the following times: T0 (about 1 month after orchi-
ectomy and before beginning cancer treatment) and 3 (T3), 6
(T6), 9 (T9), 12 (T12) and 24 (T24) months after the end of treat-
ment. Pre-treatment DNA fragmentation index (DFI) could not
be assessed for some patients, as the volume of their sperm sam-
ple was sufficient for cryobanking only. Specifically, of these 254
patients, 139 patients were evaluated pre-treatment, with 82 of
these also providing samples at various times post treatment,
and 115 patients were assessed post treatment only. Post-treat-
ment recruitment of patients was based on the recovery of
spermatogenesis, as an adequate number of spermatozoa is
essential for analysis of chromatin integrity.
Cancer treatment
A total of 141 patients (38 seminoma and 103 non-seminoma)
underwent chemotherapy. Of these, 110 were treated with BEP
(bleomycin, etoposide and cisplatin). The chemotherapy dose
and administration regimen were as follows: days 1, 2, 3, 4 and 5:
cisplatin 20 mg/m2 i.v. and etoposide 100 mg/m2 i.v.; days 2, 9
and 16: bleomycin 18 mg/m2 i.v. every 3 weeks. From one to
four BEP cycles were administered: five patients underwent
one cycle, 46 two cycles, 44 three cycles and 15 four cycles.
Twenty-three of the remaining patients underwent one/two car-
boplatin cycles and eight patients underwent one to five cycles
of other chemotherapy regimens: cisplatin or bleomycin and
polychemotherapy (cisplatin, vepesid, bleomycin).
One hundred and nine seminoma patients and four non-
seminoma patients were treated with radiotherapy of the
lumbar–aortic lymph nodes (with shielding of the remaining
testicle). The protocol involved a mean dose of 2600 cGy
(range 1800–4320 cGy).
A longitudinal study was carried out the short- and long-term
effects of chemo- and radiotherapy on chromatin integrity and
semen parameters of all testicular cancer patients. We studied
139 patients at T0, 59 patients at T3, 54 at T6, 60 at T9, 75 at T12
and 75 at T24. We then separately evaluated the effects of
chemotherapy or radiotherapy on chromatin integrity.
Semen analysis
Semen samples were collected by masturbation directly into a
sterile plastic container after 2–7 days of sexual abstinence. They
were examined by light microscope according to World Health
Organization criteria (World Health Organization, 2010). The fol-
lowing variables were taken into consideration: total sperm
count (n9106), total motility (%) and morphology (% abnormal
forms). One aliquot of each of the raw semen samples was trea-
ted for evaluation of sperm chromatin structure. The aliquots
were washed twice with NaCl 0.9% solution and the pellets
resuspended in TNE buffer containing 10% glycerol to a final
sperm concentration of 2 9 106/mL and transferred to Eppen-
dorf snap-cap tubes. The tubes were stored at 80°C until flow
cytometry (FCM) analysis.
Assessment of DNA integrity
Sperm DNA integrity was evaluated by sperm chromatin struc-
ture assay (SCSA), strictly following the procedure described in
the literature (Spano et al., 2000; Evenson et al., 2002). On the
day of analysis, samples were quickly thawed in a 37 °C water
bath and used immediately. A total of 1–2 9 106 cells were
treated with a pH 1.2 detergent solution containing 0.1% Triton
X-100, 0.15 mol/L NaCl and 0.08 mol/L HCl for 30 sec and then
stained with 6 mg/L of purified acridine orange (AO; Molecular
Probes, Eugene, OR, USA) in a pH 6.0 phosphate-citrate buffer.
Cells were analysed by a FACS Vantage flow cytometer (Becton
Dickinson, San Jose, CA, USA), equipped with an air-cooled
argon ion laser. A total of 10 000 events were accumulated for
each measurement. Under these experimental conditions, when
excited with a 488-nm light source, AO intercalated with double-
stranded DNA emits green fluorescence and AO associated with
single-stranded DNA emits red fluorescence. Sperm chromatin
damage can thus be quantified by FCM measurement of the
metachromatic shift from green (native, double-stranded DNA)
to red (denatured, single-stranded DNA) fluorescence and dis-
played as red (fragmented DNA) versus green (DNA stainability)
fluorescence intensity cytogram patterns.
Adopting the guidelines described by Evenson et al. (2002)
and using the dedicated SCSASoft software (SCSA Diagnostics,
Volga, SD, USA) for offline data analysis, we expressed the extent
of DNA denaturation in terms of DFI, the ratio of red to total
(red plus green) fluorescence intensity, that is the level of dena-
tured DNA over total DNA. The DFI value was calculated for
each sperm cell in a sample, and the percentage of spermatozoa
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with detectable DFI values was evaluated from the resulting DFI
frequency distribution histogram. The statistical DFI threshold
for infertility is established in the Georgetown Male Factor Infer-
tility Study (Evenson et al., 1999; Zinaman et al., 2000).
We also considered the fraction of highly DNA-stainable
(HDS) cells, representing the percentage of immature spermato-
zoa. These events exhibit a green fluorescence intensity higher
than the upper border of the main cluster of the sperm popula-
tion with non-detectable DFI. The percentage of these parame-
ters was calculated by setting an appropriate gate on the
scattergram (abscissa: red fluorescence, fragmented DNA; ordi-
nate: green fluorescence, native DNA stainability). Samples were
measured twice and the results reported refer to the mean value
of the two FCMmeasurements.
Statistical analysis
All quantitative results are expressed as means and SD. The
Kolmogorov–Smirnov test was used to evaluate the normal dis-
tribution of all variables. We aimed to assess whether pre- and
post-treatment semen analysis and DFI values were statistically
different. As some semen parameters and SCSA variables were
not normally distributed, we used also non-parametric tests for
paired o unpaired data to evaluate the differences between two
mean values. The different DFI values at the baseline (T0) and
post therapy were categorized by age, histotype and stage.
Patients were grouped by age into ≤30 and >30 years, by histo-
type into seminoma and non-seminoma and by stage into
pathological stage (pT1 and pT2) and clinical stage (Stage I and
Stage II). The results at T3 and T6 were combined (T3 + T6) and
compared against T0. To compare the results for DFI parameters
in the groups pT1 and pT2 and stage I and stage II, we subse-
quently calculated the relative efficacy for DFI parameter X as
(Xt  X0)/X0, where X0 is the pre-therapy value and Xt is the
value of the DFI parameter at time T3 + T6. Spearman correla-
tions were calculated between the DFI and sperm parameters
(total sperm number, total motility, absolute value of motile
spermatozoa/ejaculate and abnormal forms). A two-tailed p-
value below 0.05 was considered statistically significant. All sta-
tistical analyses were performed using GraphPad Prism v. 5
(GraphPad Software, Inc., La Jolla, CA, USA).
Multivariate analyses (ANOVA, logistic regressions) were per-
formed between DFI at T3 + T6 and the independent variables
included in the model (treatment, histotype, pathological and
clinical stage and DFI at T0).
RESULTS
Patients
We evaluated 254 testicular cancer patients aged 14–49 years
(mean  SD = 29.9  6.2), of whom 147 (57.9%) had semino-
ma and 107 (42.1%) had non-seminoma. Patients were also
classified on the basis of pathological and clinical stage (TNM
classification). Testicular descent into the scrotum at the time
of birth was found to be normal in 236 patients (92.9%), while
18 (7.0%) had a history of cryptorchidism [17 unilateral (10 on
the left and 7 on the right) and one bilateral]. Of these, 12 had
seminoma and six had non-seminoma. The tumour was in the
left testis in 121 (47.6%) patients and in the right testis in 133
(52.4%).
Semen analysis
There was a significant decrease in total sperm number in the
population as a whole from T0 (132.3  116.8 9 106/ejaculate)
to T12 (94.5  80.7 9 106/ejaculate) (p = 0.027). Differences
between sperm numbers at T0 (132.3  116.8 9 106/ejaculate)
and T24 (141.5  98.5 9 106/ejaculate) were not statistically sig-
nificant, indicating that sperm quality had returned to pre-treat-
ment values. Total motility at T0 was 42.2  13.4%; this showed
a significant decrease at T3 (32.1  17.8%, p = 0.0003), T6
(33.9  18.0%, p = 0.007) and T9 (36.9  13.0%, p = 0.004) but
had returned to near pre-treatment values by T12
(41.1  13.1%) (p = 0.502) and showed a non-significant
increase by T24 (44.9  10.8) (p = 0.201). In contrast, abnormal
forms increased significantly from T0 (75.1  6.7%) to T24
(77.6  5.5%) (p < 0.0001), with the most marked increase at T3
(80.0  8.7%) and T6 (80.2  8.1%) (Fig. 1).
DNA integrity
Sperm chromatin structure assay analysis was used to detect
sperm chromatin damage, that is increased susceptibility to par-
tial DNA denaturation induced by a weak acid treatment. DNA
chromatin integrity is expressed by the parameters DFI and
HDS. The mean DFI for all patients at T0 was 18.0  12.5%. This
increased significantly at T3 (27.7  17.4%) (p < 0.0001) and T6
(23.2  15.3%) (p = 0.011), returning to the baseline value by T9
(17.3%  8.2) (p = 0.570). There was a further significant
decrease at T12 and T24 (14.0  8.9% and 14.4  10.3% respec-
tively) (p = 0.009; p = 0.016) (Fig. 2A). The mean percentage of
HDS cells was 17.4  9.5% for all patients at T0, dropping signif-
icantly at T9 (14.5  9.0%) (p = 0.007) and continuing to drop
significantly at T12 and T24 (11.9  5.8%; 8.0  3.0%)
(p <0.0001), indicating an increased fraction of spermatozoa
with higher chromatin condensation as a function of time after
therapy.
To confirm these results, we selected 95 patients from the ori-
ginal caseload of 254 for whom both baseline and one or more
post-treatment (T3, 6, 9, 12, 24) measurements were available.
Statistical analysis against T0 (18.2%) revealed that DFI rose at
T3 (29.6%, p < 0.0001) and T6 (25.1%, p = 0.013), returned to the
baseline at T9 (17.9%, p = 0.311) and dropped significantly at
T12 (14.7%, p = 0.034) and non-significantly at T24 (15.8%,
p = 0.588). These results were similar to those for the caseload
(A) (B) (C)Figure 1 Variation in mean semen parameters
of all testicular cancer patients after chemother-
apy and radiotherapy over time (in months).
a: p < 0.001 in comparison to T0; b: p < 0.01 in
comparison to T0; c: p < 0.05 in comparison to
T0; ns: not significant.
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as a whole, and in fact there was no statistically significant
difference in DFI between the 95- and 254-patient caseload at
any time point (p > 0.05) (Fig. 2B).
As we found greater treatment-induced chromatin damage at
T3 and T6, to evaluate the effect of age, histotype and pathologi-
cal and clinical stage on chromatin integrity we compared the
DFI of the 139 patients at T0 against the 113 T3 + T6 patients, to
carry out a robust, numerically significant analysis.
Age
Patients were divided into subgroups of ≤30 and >30 years. No
statistically significant differences in DFI were seen between the
two subgroups pre- and post therapy (Table 1).
Histotype
At T0 there were 81 seminoma and 58 non-seminoma patients;
no significant differences in DFI were seen between histotypes
(p = 0.236). Comparison of post-treatment values revealed high
DFI in both histotypes (seminoma 25.7% vs. non-seminoma
25.3%); the difference was not significant (p = 0.973).
Pathological stage
At T0 there were 85 pT1 and 46 pT2 patients, with no signifi-
cant differences in DFI between the two stages (p = 0.222). Com-
parison of the baseline and post-treatment (T3 + T6) values
revealed a statistically significant post-treatment increase in DFI
for both stages (pT1 18.3% vs. 23.7%, p = 0.003, pT2 17.2% vs.
28.4%, p = 0.001). The magnitude of the increase in DFI between
the two stages was assessed by calculating the relative difference
(RD), revealing a larger increase in pT2 than in pT1 (65%
vs. 30%).
Clinical stage
At T0 there were 100 stage I and 31 stage II patients, with
no significant differences in DFI between the two stages
(p = 0.301). Comparison of the baseline and post-treatment
(T3 + T6) values revealed a statistically significant post-treat-
ment increase in DFI for stage I (17.2% vs. 25.1%, p < 0.0001)
and a non-significant increase for stage II (19.0% vs 26.8%,
p = 0.084). The RD revealed a similar increase in both stages
(45.9% vs. 41.1%).
We thus found that post-treatment DNA damage is not
affected by age or histotype, but is dependent on the stage and is
more marked in a more advanced pathological stage. These
results suggest that even if pre-treatment DFI is similar for both
stages, a more advanced pathological stage makes patients more
susceptible to treatment-induced damage. We also carried out
ANOVA and logistic regressions, which showed no statistical corre-
lation between DFI at T3 + T6 and the independent variables
included in the model (treatment, pT stage, clinical stage and
DFI at T0). This could be because of the low numbers of subjects
in some groups.
Finally, we assessed the correlation between DNA damage and
semen parameters using Spearman’s correlation on the 139 T0
patients and 113 (T3 + T6) post-treatment patients. We found a
negative correlation between DFI and total sperm count
(r = 0.21, p = 0.012) and DFI and total motility (r = 0.35,
p <0.0001) and a positive correlation between DFI and abnormal
forms (r = 0.18, p = 0.029) at T0, maintained post treatment. In
addition to raw data on percentage motility, we also considered
absolute values in terms of millions of motile spermatozoa per
ejaculate (obtained by multiplying the total spermatozoa per
ejaculate by the percentage of sperm motility). This revealed a
negative correlation between the percentage of mobile sperma-
tozoa and DFI (r = 0.27, p = 0.001).
We also examined the impact of the different treatments by
dividing the caseload into two treatment subgroups: chemother-
apy (CH) group, consisting of 141 patients who had undergone
chemotherapy, and radiotherapy (RT) group, consisting of 113
patients who had undergone radiotherapy of the lumbar–aortic
lymph nodes. More specifically, the CH group consisted of 74
patients at T0, 22 at T3, 25 at T6, 30 at T9, 39 at T12 and 43 at
T24, whereas the RT group consisted of 65 patients at T0, 37 at
T3, 29 at T6, 30 at T9, 36 at T12 and 32 at T24.
Chemotherapy group
The mean DFI value for this group at T0 was 18.9  13.5%.
This underwent a significant increase at T3 (25.5  16.7%,
p = 0.028), while at T6 (23.9  17.3%) the increase against the
baseline was not statistically significant. There was a return to
the baseline value at T9 (18.9  9.2%, p = 0.374) and a signifi-
cant decrease at T12 and T24 (11.7  7.3%, p = 0.002 and
13.4  10.4%, p = 0.007 respectively) (Fig. 3A). The HDS cell
value for this group at T0 was 16.4  8.9%. This underwent a sig-
nificant decrease at T12 (12.6  5.5%, p = 0.038) and T24
(7.7  2.9%, p <0.0001), indicating improved chromatin conden-
sation with increasing time since the end of treatment. The
increase in DNA damage from T0 to T3 + T6 as a function of
treatment intensity is shown in Table 2. Comparison of patients
undergoing 1–2 and 3–4 PEB cycles revealed an increase in post-
treatment DFI at higher treatment doses, although this was not
(A) (B)
Figure 2 Variation in DFI values pre- and post therapy over time (in
months): (A) all testicular cancer patients (254), (B) follow-up of 95 testicu-
lar cancer patients. a: p < 0.001 in comparison to T0; b: p < 0.01 in com-
parison to T0; c: p < 0.05 in comparison to T0; ns: not significant.
Table 1 Effect of treatment on sperm chromatin integrity by age group.
Comparison of two age groups (≤30 and >30 years) pre- (T0) and post ther-
apy (T3 + T6)
DFI (%) p
≤30 years >30 years
T0a 18.5 (12.7) (n = 87) b 17.1 (12.3) (n = 52) b 0.44c
T3 + T6a 26.4 (17.4) (n = 69) b 24.1 (15.0) (n = 44) b 0.68c
p value 0.001c 0.003c
aMean (standard deviation). bNumber of patients. cMann–Whitney test.
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statistically significant. The RD revealed a larger increase for 3–4
PEB cycles than for 1–2 PEB cycles (95.8% vs. 42.7%).
Radiotherapy group
The mean DFI value for this group at T0 was 17.1  11.3%.
There was a significant increase at T3 (28.9  18.0%, p = 0.0003)
and T6 (22.7  13.8%, p = 0.036). There was a non-significant
decrease from the baseline at T9 (15.5  6.6%, p = 0.876), T12
(16.4  9.9%, p = 0.658) and T24 (16.0  10.1%, p = 0.602)
(Fig. 3B). The HDS cell value for this group at T0 was
18.5  10.1%. This dropped significantly at T9 (12.4  8.5%,
p = 0.0006) and continued to drop significantly at T12 and T24
(11.1  6.0%, p < 0.0001; 8.6  3.0%, p < 0.0001). Again, this
indicated improved chromatin condensation with increasing
time since the end of treatment.
As most patients undergoing radiotherapy received a dose of
around 2550 cGy, the effect of radiotherapy intensity could not
be evaluated.
DISCUSSION
Fertilization and embryonic development are biological events
which depend on numerous factors, including sperm quality. An
excessive number of sperm DNA strand breakages has particu-
larly negative consequences for the reproductive process. Such
chromatin abnormalities may be the outcome of apoptotic pro-
cesses, oxidative stress or faulty protaminization. Antineoplastic
therapies are an important cause of sperm DNA damage. Inter-
est in the toxic effects of chemotherapeutic agents on embryonic
development has generally focussed on the mother, while the
paternal aspect has often been underrated. Few studies have
investigated male-mediated teratogenicity (Brinkworth, 2000),
but above all the little available data provide conflicting informa-
tion on sperm chromatin damage induced by these treatments.
Radiotherapy and chemotherapy can in fact impair reproductive
function through both cytological and molecular effects includ-
ing impaired spermatogenesis, resulting in oligozoospermia and
azoospermia (Trost & Brannigan, 2012), and increased aneu-
ploidy for up to 18–24 months after treatment (Martin et al.,
1999; De Mas et al., 2001; Tempest et al., 2008). While the main
aim of cancer treatment must of course be to cure the cancer
itself, the future quality of life of such patients must not be
neglected, given the increased survival rates permitted by
technological advances.
With testicular cancer, which often affects young men, repro-
ductive problems that might arise after treatment are an impor-
tant issue. Sperm chromatin impairment is of particular interest
as it may be an infertility factor and could even be associated
with genomic instability, with negative consequences for any
offspring. Information on such factors is thus of considerable
translational value in enabling the adequate counselling of
patients as to their future reproductive potential.
Literature evidence in this area is contradictory, owing to the
different methods used to study sperm DNA damage, the differ-
ent diseases and treatments under investigation and, above all,
the relatively small caseloads. A prospective longitudinal study
carried out by Stahl et al. (2004) used SCSA to evaluate the per-
sistence of any sperm DNA impairment following antineoplastic
treatment in 74 testicular cancer patients and 278 controls.
Semen examinations were carried out after orchiectomy and
before chemo- or radiotherapy and 6, 12, 24, 36 and 60 months
after the end of treatment. Patients were divided into subgroups
on the basis of their treatment: surgery and monitoring, chemo-
therapy, chemotherapy plus radiotherapy and radiotherapy
alone. The authors found a significant but transient increase in
DFI in the first 2 years after radiotherapy, which normalized
after 3–5 years, and a reduction in DFI up to 5 years post che-
motherapy. This curious result was explained by the consider-
able vulnerability of germ cells to chemotherapy, which might
cause the elimination of sperm cells with DNA damage.
Another prospective study by O’Donovan (2005) evaluated
chromatin integrity pre- and post therapy in various cancers
including testicular cancer, lymphoma (Hodgkin and non-Hodg-
kin) and leukaemia. This study involved a semen examination,
COMET assay and a chromatin condensation assay by cytofluo-
rometry using propidium iodide. Semen samples were examined
before therapy and 3, 6 and 12 months after the end of treatment
with various antineoplastic agents. There was a significant
reduction in DNA integrity and a non-significant reduction in
chromatin condensation after treatment; however, the study
involved a very small caseload of 14 fertile men and 33 cancer
patients, of whom just 13 had testicular cancer.
Another study by Stahl et al. (2009) evaluated patients with
various neoplastic diseases to establish if DNA integrity was
affected by the type of treatment, carrying out a semen examina-
tion and SCSA on the semen samples of 58 testicular cancer
patients and 137 controls. Patients were divided into subgroups
on the basis of the treatment (mean time 3 years, low- and high-
dose chemotherapy, combined chemotherapy/radiotherapy
and radiotherapy alone). The authors found no significant differ-
ences in pre- and post-treatment DFI, demonstrating that DNA
integrity was not affected by the treatment.
However, O’Flaherty et al. (2010) in a prospective study
obtained different results. These authors studied 16 patients
Table 2 Sperm DNA damage increase from T0 to T3 + T6 and treatment
intensity
Chemotherapy DFI (%) RD p value
T0 (pts) T3 + T6 (pts)
1–2 BEP cycles 19.9 (29) 28.4 (19) 42.7 0.0748
3–4 BEP cycles 16.6 (29) 32.5 (14) 95.8 0.0011
p value 0.7855 0.3920
DFI, DNA fragmentation index; RD, relative difference.
(A) (B)
Figure 3 Variation in total DFI values over time (in months): (A) after che-
motherapy, (B) after radiotherapy. a: p < 0.001 in comparison to T0; b:
p < 0.01 in comparison to T0; c: p < 0.05 in comparison to T0; ns: not
significant.
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with testicular cancer after orchiectomy who underwent BEP
and 16 patients with Hodgkin’s disease who underwent ABVD.
The controls consisted of 11 healthy male volunteers. Sperm
DNA integrity was evaluated using COMET assay at various
times after the end of chemotherapy: 0, 6, 12, 18 and 24 months.
This longitudinal study found that chemotherapy had a negative
impact on both Hodgkin’s disease and testicular cancer patients,
with increased sperm DNA fragmentation 6 months after the
end of treatment in comparison with the baseline; this value
remained elevated up to 18–24 months.
Smit et al. (2010) evaluated DNA integrity in patients with var-
ious cancers, including 52 testicular cancer patients before treat-
ment and 25 after a follow-up of 0.5–3.3 years after the end of
treatment. Patients were divided into subgroups on the basis of
their treatment: BEP, BEP combined with radiotherapy, or radio-
therapy alone. This study found a drop in post-therapy DFI
when considering all testicular cancer patients, but a significant
increase after radiotherapy in comparison with chemotherapy
alone.
A different study (Romerius et al., 2010) evaluated sperm DNA
integrity in 99 childhood cancer survivors with different onco-
logical diagnosis who received different types of treatment. The
median age (range) at diagnosis was 10 years (0.1–17 years) and
at the time of examination 30 years (20–46 years). These authors
found that childhood cancer per se is associated with increased
sperm DNA damage. In fact, the increased DFI in the group that
received neither radiotherapy nor chemotherapy might imply
that childhood cancer patients had some kind of genomic insta-
bility. The study also found that DFI might be additionally
increased by radiotherapy and reduced by cytotoxic treatment.
A more recent study by O’Flaherty et al. (2012) evaluated chro-
matin packaging defects in cancer survivors after chemotherapy.
Various methods were used to evaluate chromatin integrity in
addition to SCSA. All tests were carried out at T0 and 6, 12, 18
and 24 months after the end of treatment. The study involved
just 16 patients with testicular cancer after orchiectomy, 15
patients with Hodgkin’s disease, 11 infertile controls and 11 fer-
tile controls. In the testicular cancer patients, high levels of DNA
damage were found up to 24 months post therapy, with low pre-
therapy chromatin compaction in comparison with fertile con-
trols. These data suggest that the chromatin structure is less
resistant because of reduced DNA compaction.
A recent multicentre prospective study by Bujan et al. (2013)
evaluated semen parameters of 129 testicular cancer patients
before and after antineoplastic treatment, of whom 53 patients
underwent sperm DNA integrity testing by SCSA and TUNEL at
the baseline and 3, 6, 12 and 24 months after the end of chemo-
or radiotherapy. The authors found only HDS to be increased at
T6 in radiotherapy patients, indicating impaired chromatin con-
densation shortly after the end of the treatment.
In our longitudinal study, we evaluated sperm DNA integrity
and spermatogenesis in a large caseload of testicular cancer
patients pre- and post treatment. We found a post-treatment
reduction in total sperm number from the baseline up to T12
and in motility up to T9; these parameters then improved
progressively, returning to near-baseline values by T24. The per-
centage of abnormal forms increased more strongly at T3, T6
and T9, dropping at T12 and T24, even if there was still a signifi-
cant difference with respect to T0. These data are in agreement
with a previous study we conducted on the effects of chemo-
and radiotherapy on spermatogenesis (Gandini et al., 2006), in
which we demonstrated that spermatogenesis recovery is a func-
tion of the time since the end of the therapy, with 94% of chemo-
therapy patients and 93% of radiotherapy patients showing good
recovery after 12 months and 97 and 94%, respectively, after
24 months. We also showed that the recovery of spermatogene-
sis after chemo- or radiotherapy was not a function of pre-ther-
apy sperm parameters. Given the recovery of spermatogenesis
12–24 months after the treatment end, we considered the possi-
bility of a time-dependent difference in sperm chromatin integ-
rity between pre- and post-chemotherapy/radiotherapy. No
significant difference in pre-treatment (T0) sperm DFI in cancer
patients was found between the two histotypes (seminoma and
non- seminoma), between the two pathological stages (pT1 and
pT2) or between the two clinical stages (I and II). Analysis at T3,
T6, T9, T12, T24 demonstrated that the sperm chromatin profile
is markedly impaired 3 and 6 months after the treatment end,
returning to the baseline at T9 and improving considerably at
T12 and T24. This is supported by the results of the HDS analysis
used to assess sperm DNA compaction indirectly. HDS levels at
T12 and T24 are significantly lower than at T0, indicating
increased chromatin condensation with increasing time since
the end of the treatment.
As our data demonstrate that sperm DNA damage is greatest
at T3 + T6, we also investigated if the treatment effects on sperm
chromatin integrity were influenced by age, histotype or stage,
finding that post-treatment DNA damage is not age or histotype
dependent but is a function of pathological and clinical stage
and is more marked in a more advanced pathological stage.
Although this needs to be confirmed in larger caseloads, it is a
particularly interesting finding, as it suggests that spermatozoa
from patients with greater tumour-induced impairment of the
testicular structure are more vulnerable to damage caused by
antineoplastic treatments. We also examined the impact of the
different treatments on sperm chromatin integrity by dividing
the caseload into two treatment subgroups: chemotherapy and
radiotherapy. After chemotherapy, we found a marked increase
in DFI at T3 and T6 and a significant reduction at T12 and T24 in
comparison with the baseline, thus revealing a clear improve-
ment in the chromatin profile at the later times. In contrast, after
radiotherapy DFI increased at T3 and T6 but the reduction was
far less marked, reaching the baseline values at T12 and T24.
These results are in line with previous literature studies, suggest-
ing that radiotherapy induces greater damage because of disper-
sion of radiation during the treatment. Finally, we investigated
the correlation between DNA damage and pre- and post-treat-
ment semen parameters, finding a negative correlation between
DFI and total sperm number, total motility and number of
motile spermatozoa and a positive correlation between DFI and
abnormal forms. These data demonstrate for the first time that
sperm chromatin damage is more extensive when there is
greater quantitative and qualitative pre- and post-treatment
impairment of spermatogenesis. We also demonstrated that the
chromatin profile may be affected in the months immediately
following the end of the treatment, improving after 12–
24 months.
It should be stressed that our results refer only to testicular
cancer and only to the antineoplastic treatments specific for this
disease. Different treatments can in fact cause different types of
nuclear damage and the methods currently in use for the study
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of chromatin profile provide only an incomplete picture of such
damage, especially as these treatments can cause long-term
changes in gene expression profile and methylation pattern, with
a possible impact on embryonic development.
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